Influence of broperamole, a new antiinflammatory agent, on gastrointestinal microbleeding in the dog.
59Ferrous sulfate was administered i.v. to 12 male beagles. Beginning 11 days later, gastrointestinal microbleeding was determined by comparison of the 59Fe specific activities of 24-h stool collections and of whole blood. During the following 48-day period the dogs received p.o. twice daily a placebo, two tablets containing 650 mg of acetylsalicylic acid (ASA), 22 mg/kg of phenylbutazone, or 24 mg/kg of N-2-[5'-(3"-bromophenyl-2'H-tetrazole]propionyl piperidine (broperamole) in four 7-day tratment periods (each of which was preceded by a 5-day period of no treatment) in complete crossover fashion. Average daily fecal blood volumes of 2.55 ml, 1.94 ml, 0.54 ml, and 0.48 ml were observed after treatment with ASA, phenylbutazone, broperamole, and placebo, respectively. The influence of ASA and phenylbutazone on gastrointestinal microbleeding was statistically greater than that of broperamole, which was equivalent to placebo.